Osteotech stops polymer research:
This article was originally published in Clinica
Executive Summary
Osteotech has discontinued its polymer R&D programme which included the development of an adhesion barrier and an artificial skin product. Furthermore, the company has stopped marketing its OsteoActive bone substitute. The bone void filler was launched in Europe in late 1995. The measures are part of a restructuring programme to cut spending by more than $1 million a year and to make the European operations profitable. Osteotech will focus on building its revenues by producing ceramic and titanium plasma spray coating services and ceramic powders and products.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.